Gestodene

synthetic steroid with progestational activity; RN given refers to (17alpha)-isomer

Also Known As:

13-ethyl-17-hydroxy-18,19-dinor-17 alpha-pregna-4,15-dien-20-yn-3-one; 17-alpha-ethinyl-13-ethyl-17 beta-hydroxy-4,15-gonadien-3-one; 18,19-dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)-; Gestoden; Gestodene, ((17alpha)-(+-))-isomer; SH B 3331

Networked: 181 relevant articles (3 outcomes, 40 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Fused-Ring Compounds
  - Steroids: 70059
    - Norsteroids: 16
      - Norpregnanes: 2
        Norpregnenes
        Gestodene: 181

Experts

1.	Casoy, Julio: 6 articles (01/2014 - 10/2006)
2.	Maia, Hugo: 6 articles (01/2014 - 10/2006)
3.	Helmerhorst, Frans M: 5 articles (03/2014 - 05/2002)
4.	Lidegaard, Øjvind: 4 articles (10/2014 - 08/2009)
5.	Rosendaal, Frits R: 4 articles (03/2014 - 05/2002)
6.	Løkkegaard, Ellen: 3 articles (06/2012 - 08/2009)
7.	Athayde, Célia: 3 articles (04/2010 - 10/2006)
8.	Correia, Tânia: 3 articles (04/2010 - 10/2006)
9.	Helmerhorst, F M: 3 articles (08/2009 - 08/2002)
10.	Cianci, Antonio: 2 articles (02/2018 - 09/2010)

Related Diseases

1.	Metrorrhagia (Spotting) 01/01/1987 - "In the total number of gestodene cycles in studies A and B, there was a 6.9% incidence of spotting, a 0.8% incidence of breakthrough bleeding, and a 0.7% incidence of both spotting and breakthrough bleeding in studies A and B patients taking gestodene. " 01/01/2011 - "She referred with metrorrhagia of about one year, and was being treated with Ethynylestradiol/Gestodene. " 10/01/1995 - "With respect to cycle control, there is a trend towards a lower incidence of intermenstrual bleeding in the gestodene group. " 09/01/1994 - "Gestodene group exhibited significantly better cycle control as evidenced by the lower incidence of breakthrough bleeding and spotting. " 10/01/1993 - " On the other hand, breakthrough bleeding occurred less often in women in the gestodene group (19.3% vs. 29.6%). "
2.	Endometriosis 03/01/2008 - "Endometrial biopsies were taken at the time of laparoscopy in 40 patients with endometriosis, 16 of whom were using an oral contraceptive containing gestodene at the time of laparoscopy. " 03/01/2008 - "Oral contraceptives containing gestodene are effective in decreasing aromatase expression in the eutopic endometrium of patients with endometriosis." 01/01/2012 - "After a conservative surgery, 84 patients with symptomatic endometriosis were randomized to receive either intramuscular DMPA (150 mg) every 12 weeks for 24 weeks or continuous OC pills (ethinyl estradiol 0.03 mg and gestodene 0.075 mg) daily for 24 weeks. " 03/01/2008 - "To determine the effect of oral contraceptives containing gestodene on aromatase expression in the endometrium of patients diagnosed with endometriosis. " 04/01/2009 - "Progestins, such as gestodene and danazol, are potent inhibitors of aromatase expression in the endometrium, and the use of vaginal rings with danazol in doses that do not block ovulation is associated with the occurrence of pregnancy in patients with severe endometriosis without the need for surgery. "
3.	Hyperandrogenism 01/01/1991 - " Moreover, the lack of androgenic effects makes desogestrel and gestodene appropriate treatment agents for hyperandrogenism." 09/01/2010 - "This randomized study's aim was to compare the effect of four oral contraceptives (OCs) containing 30 mcg of ethinylestradiol (EE) and different progestogens [drospirenone, (DRSP), chlormadinone acetate (CMA), desogestrel (DSG), gestodene (GSD)] on biochemical and hormonal parameters of hyperandrogenism and sex hormone-binding globulin (SHBG) in women with polycystic ovary syndrome (PCOS). " 02/01/2018 - "Levonorgestrel is an androgenic progestin, but now there is the possibility of choosing progestins without androgenic effect (gestodene and desogestrel) or progestins with antiandrogenic effect (cyproterone acetate, dienogest, drospirenone, chlormadinone acetate), very useful in patients with hyperandrogenism. "
4.	Venous Thromboembolism 05/01/2010 - "Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare"." 12/01/1997 - "The British Committee on Safety of Medicines' issuance of a public notice of the existence of an increased risk of venous thromboembolism (VTE) from using third-generation pills containing gestodene or desogestrel fomented considerable controversy in late 1995. " 11/08/1996 - " In New Zealand, about 75% of OC users (compared to 50% in the UK) use these new OCs and about 40 of the 50 expected cases of venous thromboembolism in New Zealand pill users per year will occur in women taking OCs containing desogestrel or gestodene." 11/08/1996 - " In 1995, the UK Committee on the Safety of Medicines advised physicians not to prescribe OCs containing desogestrel or gestodene to women with risk factors for venous thromboembolism and recommended that current users should continue with these preparations only if they could not tolerate other OCs. " 01/01/1996 - " These data appear to completely contradict the earlier allegation of a differential risk for venous thromboembolism (VTE) between desogestrel- and gestodene-based combined OCs. "
5.	Hemorrhage 04/01/2007 - "This is in contrast to regimens containing gestodene, where smoking women are less likely to differ from non-smoking women with regard to bleeding. " 04/01/2000 - "The latent period before withdrawal bleeding was significantly longer for monophasic gestodene at cycles 1-5 and 8-10 (p < 0.05). " 03/01/1994 - "Significantly less bleeding was seen in the gestodene group during cycle 2 (p = 0.02). " 10/01/1995 - "The incidence of spotting (scanty bleeding) during the important first three cycles was 3.5% lower in the gestodene group, and over the first six cycles, it was 7.6% lower. " 10/01/1992 - "In contrast, clinical tolerance with the new progestins such as gestodene is good; in one study 86% of patients had normal bleeding patterns. "

Related Drugs and Biologics

1.	Oral Contraceptives
2.	Desogestrel
3.	Progestins (Progestagens)
4.	Levonorgestrel (Plan B)
5.	Contraceptive Agents (Contraceptives)
6.	drospirenone
7.	Cyproterone Acetate
8.	Chlormadinone Acetate (Chlormadinone)
9.	Aromatase (CYP19)
10.	dienogest

Related Therapies and Procedures

1.	Contraception (Birth Control)
2.	Stents
3.	Glycemic Control
4.	Female Contraceptive Devices (Vaginal Ring)
5.	Hormonal Contraception